https://www.selleckchem.com/pr....oducts/Romidepsin-FK
However, hormone receptor-negative and HER2+ showed cytoplasmic or diminished IGF1R expression. CONCLUSION These luminal subtypes may benefit from targeted IGFR therapy in the future. BACKGROUND/AIM Recent studies suggested that patients with oligometastases have a better prognosis compared with those who have widespread dissemination. In both groups, radiotherapy is a commonly applied treatment. Patient-reported symptoms might depend on the burden of disease. Possibly, oligometastatic patients report lower scores for symptoms,
Curtir
Comentario
Compartilhar
